1.46%
3.03%
15.31%
15.08%
3.39%
-8.66%
-11.49%
AI Spotlight on JAZZ
Company Description
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally.The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer.
The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder.The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc.Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Market Data
| Last Price | 126.88 |
| Change Percentage | 1.46% |
| Open | 125.31 |
| Previous Close | 125.05 |
| Market Cap ( Millions) | 7671 |
| Volume | 262921 |
| Year High | 134.17 |
| Year Low | 99.06 |
| M A 50 | 122.51 |
| M A 200 | 113.22 |
Financial Ratios
| FCF Yield | 14.73% |
| Dividend Yield | 0.00% |
| ROE | 12.06% |
| Debt / Equity | 148.23% |
| Net Debt / EBIDTA | 273.53% |
| Price To Book | 1.87 |
| Price Earnings Ratio | 16.82 |
| Price To FCF | 6.79 |
| Price To sales | 1.92 |
| EV / EBITDA | 8.03 |
News
- Jan -22 - 3 Biotech Stocks With Notable Insider Buying
- Jan -13 - 3 Oversold Biotech Names
- Dec -23 - Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
- Dec -17 - Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec -16 - Jazz Pharmaceuticals Announces CEO Succession Plan
- Dec -11 - 5 High ROE Stocks to Buy as Volatility Weighs on Markets
- Dec -06 - Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting
- Dec -05 - Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
- Dec -04 - Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
- Dec -03 - Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting
- Nov -29 - Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet
- Nov -21 - JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
- Nov -21 - Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment
- Nov -21 - Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
- Nov -19 - Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
- Nov -14 - Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock?
- Nov -13 - Jazz (JAZZ) Upgraded to Buy: Here's Why
- Nov -13 - JAZZ or CTLT: Which Is the Better Value Stock Right Now?
- Nov -13 - Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High?
- Nov -11 - Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pharmaceutical Products
Expected Growth : 5.0 %
What the company do ?
Jazz Pharmaceuticals plc develops and commercializes pharmaceutical products for sleep and hematology/oncology, including Xyrem, Erwinaze, and Vyxeos.
Why we expect these perspectives ?
Jazz Pharmaceuticals' 5.0% growth in Pharmaceutical Products is driven by increasing demand for its sleep disorder treatments, Xyrem and Sunosi, as well as growing sales of its cancer therapy, Vyxeos. Additionally, the company's strategic acquisitions and partnerships, such as its deal with PharmaMar, have expanded its product portfolio and enhanced its R&D capabilities.
Jazz Pharmaceuticals Plc Products
| Product Range | What is it ? |
|---|---|
| Xyrem | A sodium oxybate oral solution used to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy. |
| Erwinaze | A asparaginase enzyme used to treat acute lymphoblastic leukemia (ALL) in patients who have developed hypersensitivity to E. coli-derived asparaginase. |
| Vyxeos | A liposomal formulation of daunorubicin and cytarabine used to treat adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). |
| Defitelio | A defibrotide sodium injection used to treat severe hepatic veno-occlusive disease (VOD) in patients who have undergone hematopoietic stem cell transplantation. |
| Zygel | A transdermal cannabidiol gel used to treat Fragile X syndrome, a rare genetic disorder. |
Jazz Pharmaceuticals plc's Porter Forces
Threat Of Substitutes
Jazz Pharmaceuticals plc has a moderate threat of substitutes due to the presence of alternative treatments and therapies for sleep disorders and oncology.
Bargaining Power Of Customers
Jazz Pharmaceuticals plc has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative suppliers.
Bargaining Power Of Suppliers
Jazz Pharmaceuticals plc has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and manufacturing services.
Threat Of New Entrants
Jazz Pharmaceuticals plc has a high threat of new entrants due to the growing demand for sleep disorders and oncology treatments, making it an attractive market for new entrants.
Intensity Of Rivalry
Jazz Pharmaceuticals plc operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 60.54% |
| Debt Cost | 4.32% |
| Equity Weight | 39.46% |
| Equity Cost | 7.09% |
| WACC | 5.41% |
| Leverage | 153.40% |
Jazz Pharmaceuticals plc : Quality Control
Jazz Pharmaceuticals plc passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| ZEAL.CO | Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, … |
| ALK-B.CO | ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis … |
| ALKS | Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its … |
| GMAB.CO | Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with … |
| MRUS | Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
ALK-Abelló
A-Score
1-Year Total Return ->
🥈
Genmab
A-Score
1-Year Total Return ->
🥉
Jazz Pharmaceuticals
A-Score
1-Year Total Return ->
4
Alkermes
A-Score
1-Year Total Return ->
5
Zealand Pharma
A-Score
1-Year Total Return ->
6
